EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic Pharmacokinetics of Investigational Sirolimus Topical Gel 3.9% Under Maximal Use Conditions in Microcystic Lymphatic Malformations: Results From the Phase 3 SELVA PK-MuST

Joyce Teng, Kristen Kahle, James Treat, Denise Adams, Sally Cohen-Cutler, Michael Kelly, Megha Tollefson, Amy Theos, Jeffrey Martini, Wes Kaupinen, Emily Cook, Andrea Zaenglein und 6 weitere

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s833

DOI: 10.25251/p1scfs43 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Joyce Teng und 17 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Microcystic lymphatic malformations (mLM) are rare, serious, lifelong vascular anomalies driven by somatic PI3K/mTOR pathway mutations, causing lymphorrhea, bleeding, and susceptibility to infection. No FDA-approved therapies exist, and current invasive treatments (surgery, sclerotherapy, laser) are associated with frequent recurrence. Oral sirolimus has demonstrated clinical benefit in certain lymphatic malformations, but its efficacy in cutaneous microcystic LMs is limited because sirolimus is intrinsically difficult to deliver into skin due to its large molecular size, high lipophilicity, and poor aqueous solubility, constraining therapeutic drug concentrations in affected skin tissue. Chronic systemic administration also carries risk of immunosuppression and other mTOR-related systemic toxicities. Topical sirolimus 3.9% anhydrous gel, developed on the proprietary and patented QTORIN™ platform, was engineered for enhanced solubility and sustained dermal penetration with limited systemic absorption. A pharmacokinetic maximal use substudy (PK-MuST) was conducted as part of the Phase 3 SELVA trial to evaluate systemic exposure at the upper bound of anticipated clinical use.

Objective

To characterize the systemic pharmacokinetic (PK) profile of sirolimus following topical application under maximal use conditions and to contextualize this exposure relative to known oral sirolimus PK parameters.

Methods

PK-MuST enrolled 24 participants with mLM (5 children 6 to

Zitieren

APA

Teng, J., Kahle, K., Treat, J., Adams, D., Cohen-Cutler, S., Kelly, M., Tollefson, M., Theos, A., Martini, J., Kaupinen, W., Cook, E., Zaenglein, A., Ricci, K., Nieman, E., Iacobas, I., White, M., Swaminathan, N., & Beuthe, M. G. (2026). Systemic Pharmacokinetics of Investigational Sirolimus Topical Gel 3.9% Under Maximal Use Conditions in Microcystic Lymphatic Malformations: Results From the Phase 3 SELVA PK-MuST. SKIN The Journal of Cutaneous Medicine, 10(6), s833. https://doi.org/10.25251/p1scfs43

Vancouver

Teng J, Kahle K, Treat J, Adams D, Cohen-Cutler S, Kelly M, et al. Systemic Pharmacokinetics of Investigational Sirolimus Topical Gel 3.9% Under Maximal Use Conditions in Microcystic Lymphatic Malformations: Results From the Phase 3 SELVA PK-MuST. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s833. doi:10.25251/p1scfs43

BibTeX
@article{Teng2026,
  author = {Teng, Joyce and Kahle, Kristen and Treat, James and Adams, Denise and Cohen-Cutler, Sally and Kelly, Michael and Tollefson, Megha and Theos, Amy and Martini, Jeffrey and Kaupinen, Wes and Cook, Emily and Zaenglein, Andrea and Ricci, Kiersten and Nieman, Elizabeth and Iacobas, Ionela and White, Michael and Swaminathan, Neeraja and Beuthe, Maria Gnarra},
  title = {Systemic Pharmacokinetics of Investigational Sirolimus Topical Gel 3.9% Under Maximal Use Conditions in Microcystic Lymphatic Malformations: Results From the Phase 3 SELVA PK-MuST},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s833},
  doi = {10.25251/p1scfs43}
}
Kostenlos starten →